ZUG, Switzerland — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that two articles have been published back-to-back in the same...

HANOVER, New Hampshire – Among people with cystic fibrosis (CF) who develop kidney failure, getting a kidney transplant may extend survival by nearly two decades compared with other types of care, a new study found. The transplanted kidneys also showed favorable long-term outcomes in people with CF, remaining functional for about...

MADRID, Spain – Treatment with VPRIV (velaglucerase alfa) was generally safe and showed benefits — including stable blood levels — among children and adolescents with Gaucher disease type 1, a new review of published studies has found. Evidence also suggests the approved enzyme replacement therapy (ERT) may help manage nonneurological symptoms in children with Gaucher...